title: In vivo pharmacological evaluation of two novel type II (inducible) nitric oxide synthase inhibitors.
abstract: Selective type II (inducible) nitric oxide synthase (NOS) inhibitors have several potential therapeutic applications, including treatment of sepsis, diabetes, and autoimmune diseases. The ability of two novel, selective inhibitors of type II NOS, S-ethylisothiourea (EIT) and 2-amino-5,6-dihydro-6-methyl-4H-1,3-thiazine (AMT), to inhibit type II NOS function in vivo was studied in lipopolysaccharide (LPS) treated rats. Type II NOS activity was assessed by measuring changes in plasma nitrite and nitrate concentrations ([NOx]). Both EIT and AMT elicited a dose-dependent and > 95% inhibition of the LPS-induced increase in plasma [NOx]. The ED50 values for EIT and AMT were 0.4 and 0.2 mg/kg, respectively. In addition, the administration of LPS and either NOS inhibitor resulted in a dose-dependent increase in animal mortality; neither compound was lethal when administered alone. Pretreatment with L-arginine (but not D-arginine) prevented the mortality, while not affecting the type II NOS-dependent NO production, suggesting the toxicity may be due to inhibition of one of the other NOS isoforms (endothelial or neuronal). Thus, although EIT and AMT are potent inhibitors of type II NOS function in vivo, type II NOS inhibitors of even greater selectivity may need to be developed for therapeutic applications.
authors.affiliation: Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL, USA.
authors.forename: W R
authors.initials: WR
authors.lastname: Tracey
authors.forename: M
authors.initials: M
authors.lastname: Nakane
authors.forename: F
authors.initials: F
authors.lastname: Basha
authors.forename: G
authors.initials: G
authors.lastname: Carter
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D007550:Isothiuronium / Q000031:analogs & derivatives / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D009569:Nitric Oxide / Q000494:pharmacology*; D019001:Nitric Oxide Synthase / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018805:Sepsis / Q000188:drug therapy; D013843:Thiazines / Q000494:pharmacology
chemical_list: D004791:Enzyme Inhibitors; D008070:Lipopolysaccharides; D013843:Thiazines; D007550:Isothiuronium; C007687:etiron; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase